Related Experiment Video
Updated: Jun 27, 2026
04:08
Mouse Model of Surgical Uterine Injury and Subsequent Pregnancy Outcomes
Published on: June 27, 2025
Misoprostol and congenital anomalies
R Brasil1, H Lutéscia Coelho, B D'Avanzo
1Grupo de Prevenção ao Uso Indevido de Medicamentos, Federal University of Ceará, Fortaleza, Brazil.
Pharmacoepidemiology and Drug Safety
|November 26, 2008
Summary
Mothers using misoprostol during pregnancy face an increased risk of having babies with congenital anomalies. This study highlights a potential link between misoprostol exposure and various birth defects.
Area of Science:
- Obstetrics and Gynecology
- Teratology
- Neonatal Health
Background:
- Congenital anomalies represent a significant public health concern.
- Understanding medication risks during pregnancy is crucial for maternal and infant well-being.
- Misoprostol is a medication with various therapeutic uses, including in obstetrics.
Purpose of the Study:
- To investigate the association between maternal misoprostol use during pregnancy and the occurrence of congenital anomalies in newborns.
- To quantify the risk of adverse birth outcomes linked to prenatal misoprostol exposure.
Main Methods:
- A hospital-based case-control study was conducted.
- Cases comprised 37 infants with congenital anomalies weighing less than 1500g.
- Controls included 387 infants without congenital anomalies, also weighing less than 1500g.
Main Results:
- Maternal self-reported misoprostol use was associated with an increased risk of congenital anomalies.
- The multivariate odds ratio for congenital anomalies in misoprostol-exposed infants was 2.4 (95% CI: 1.0-6.2).
Conclusions:
- Prenatal exposure to misoprostol may be associated with a wide range of congenital anomalies.
- Further research is warranted to confirm these findings and elucidate potential mechanisms.
Related Concept Videos
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:28Development of the Oral Microbiota
The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
01:19Mitral Valve Prolapse III: Nursing Management
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...